6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

June 2017

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒                Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ☐                No  ☒

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-                .

EXHIBITS

Exhibit Number	Description of Exhibits
99.1	Notice to Stock Exchanges re: Clarification on news item appearing in Business Standard dated June 14, 2017 captioned “Dr Reddy’s recalls 3.25L cartons Cipla-made acne drug from US.”, dated June 15, 2017.
99.2	Notice to Stock Exchanges re: Audit of Formulations manufacturing plant at Srikakulam, Andhra Pradesh by the U.S. FDA, dated June 16, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date: June 19, 2017	By:	/s/ Sandeep Poddar
	Name:	Sandeep Poddar
	Title:	Company Secretary

EX-99.1

Exhibit 99.1

	Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507
	Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email: mail@drreddys.com www.drreddys.com

June 15, 2017
Surveillance Department	National Stock Exchange of India Ltd.
BSE Limited	“Exchange Plaza”
Dalal Street, Fort	Bandra-Kurla Complex, Bandra (East),
Mumbai – 400 001	Mumbai – 400 051
Fax Nos.: 022-22723121 / 22723719 /	Fax Nos.: 022-26598120/ 26598237/
22722037 / 22722039	26598238
Scrip Code: 500124	Scrip Code: DRREDDY-EQ

Dear Sirs,

Ref.: Your email dated June 14, 2017

Sub: Clarification on news item appearing in Business Standard dated June 14, 2017 captioned ‘Dr Reddy’s recalls 3.25L cartons Cipla-made acne drug from US.’

This is with reference to your email dated June 14, 2017, seeking clarification on the above subject.

In this regard, we would like to state that the Company has voluntarily recalled Cipla-made Zenatane (isotretinoin) capsules used for treatment of severe acne, from the US markets. This recall is in conformance with our quality assurance norms.

The Company believes that recall of products by the Company is a usual activity in the normal course of pharmaceutical industries’ business operations. Further, the overall impact on the Company’s financials of this recall is not likely to be significant.

We regularly inform all concerned on material events and presently do not have any other information which is material to the Company’s operations or consolidated results.

This is for your information.

With regards,

/s/ Sandeep Poddar            

Sandeep Poddar

Company Secretary

CC: New York Stock Exchange Inc.(Stock Code: RDY)

EX-99.2

Exhibit 99.2

	Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507
	Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email: mail@drreddys.com www.drreddys.com

June 16, 2017

Corporate Relationship Department	National Stock Exchange of India Ltd.
BSE Limited	“Exchange Plaza”
Dalal Street, Fort	Bandra-Kurla Complex, Bandra (East),
Mumbai – 400 001	Mumbai – 400 051
Fax Nos.: 022-22723121 / 22723719 /	Fax Nos.: 022-26598120/ 26598237/
22722037 / 22722039	26598238
Scrip Code: 500124	Scrip Code: DRREDDY-EQ

Dear Sirs,

Sub: Intimation

This is to inform you that the audit of our Formulations Srikakulam Plant (SEZ) Unit I, Andhra Pradesh, by the US FDA, has been completed today. We have been issued a Form 483 with one observation, which we are addressing.

This is for your information.

With regards,

/s/ Vikas Sabharwal        

Vikas Sabharwal

Assistant Company Secretary

Encl: As above

CC: New York Stock Exchange Inc.(Stock Code: RDY)